Enhancing Adoptive T Cell Therapy Using c-Myb

Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient, the T cells attack and kill cancer cells that express the antigen, thereby treating the patient. Although ACT holds a great deal of promise, there are still technical drawbacks to be overcome, such as loss of anti-tumor activity due to T cell senescence.

This invention addresses this technical drawback by using T cells that express the transcription factor c-Myb (or a functional variant thereof) at elevated levels as the host for transduction with CARs or TCRs. T cells that exhibit elevated expression of c-Myb display inhibited differentiation, allowing the cells to survive, proliferate and serve in a therapeutic capacity for a longer duration. Since it is believed that these characteristics can increase the effectiveness of ACT, T cells with elevated levels of c-Myb expression are strong candidates for use in ACT.

Potential Commercial Applications: Competitive Advantages:
  • Adoptive cell therapy using chimeric antigen receptors (CARs), or engineered T cell receptors (TCRs)
  • Treatment of cancers that express a specific cell surface protein
  • Elevated expression of c-Myb in T cells allows them to resist differentiation, allowing the cells to survive and proliferate in greater numbers
  • Increased survival and proliferation of T cells allows for a prolonged therapeutic effect

Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
  • Ex vivo data available


Sanjivan Gautam (NCI)  ➽ more inventions...

Yun Ji (NCI)  ➽ more inventions...

Luca Gattinoni (NCI)  ➽ more inventions...

Intellectual Property:
US Application No. 62/209,497
PCT Application No. PCT/US2016/048435
US Application No. 15/754,078

Collaboration Opportunity:

The NCI ETIB is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize c-Myb overexpression for cancer immunotherapy. For collaboration opportunities, please contact John D. Hewes, Ph.D. at john.hewes@nih.gov.

Licensing Contact:
Abritee Dhal,
Email: abritee.dhal@nih.gov
Phone: 240-276-5530

OTT Reference No: E-232-2015-0
Updated: Nov 4, 2015